Squarepoint
ORIC icon

Squarepoint’s Oric Pharmaceuticals ORIC Stock Holding History

Squarepoint’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73M Buy
+344,343
New +$3.12M ﹤0.01% 1835
2026
Q1 		– Sell
-229,383
Closed -$1.88M – 4769
2025
Q4 		$1.88M Buy
229,383
+198,650
+646% +$2.29M ﹤0.01% 2112
2025
Q3 		$369K Sell
30,733
-76,034
-71% -$800K ﹤0.01% 3504
2025
Q2 		$1.08M Buy
+106,767
New +$717K ﹤0.01% 2598
2024
Q4 		– Sell
-16,666
Closed -$171K – 5381
2024
Q3 		$171K Sell
16,666
-17,318
-51% -$171K ﹤0.01% 3743
2024
Q2 		$240K Buy
33,984
+16,613
+96% +$149K ﹤0.01% 3556
2024
Q1 		$239K Sell
17,371
-8,685
-33% -$103K ﹤0.01% 3525
2023
Q4 		$240K Buy
+26,056
New +$188K ﹤0.01% 3489
2023
Q2 		– Sell
-37,400
Closed -$213K – 3881
2023
Q1 		$213K Buy
+37,400
New +$195K ﹤0.01% 2769
2022
Q3 		– Sell
-59,073
Closed -$265K – 3308
2022
Q2 		$265K Buy
59,073
+45,293
+329% +$181K ﹤0.01% 2349
2022
Q1 		$74K Buy
+13,780
New +$124K ﹤0.01% 2646
2021
Q2 		– Sell
-10,342
Closed -$253K – 3573
2021
Q1 		$253K Buy
+10,342
New +$327K ﹤0.01% 2535

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's ORIC Position: Q2 2026 in Review

Squarepoint opened a new position in Oric Pharmaceuticals (ORIC) in Q2 2026: 344,343 shares worth $3.73M. The stake represents ﹤0.01% of the portfolio and ranks #1835 among its holdings. This is a return to the name: Squarepoint previously reported a position in ORIC as recently as Q4 2025.

Squarepoint first reported a position in ORIC in Q1 2021 and has held it in 12 quarters since. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Squarepoint held 344,343 shares of Oric Pharmaceuticals worth $3.73M as of Q2 2026.
  • Oric Pharmaceuticals was a new Squarepoint position in Q2 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1835 holding.
  • Squarepoint first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.